Should I buy or sell Artivion stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AORT shares. View AORT analyst ratings or view top-rated stocks .

What is Artivion's stock price target for 2024?

2 brokerages have issued 12 month price objectives for Artivion's shares. Their AORT share price targets range from $22.00 to $25.00. On average, they anticipate the company's share price to reach $23.50 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View analysts price targets for AORT or view top-rated stocks among Wall Street analysts .

How have AORT shares performed in 2024?

Artivion's stock was trading at $17.88 at the beginning of 2024. Since then, AORT shares have increased by 14.1% and is now trading at $20.41. View the best growth stocks for 2024 here .

When is Artivion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AORT earnings forecast .

How were Artivion's earnings last quarter?

Artivion, Inc. (NYSE:AORT) issued its quarterly earnings results on Thursday, February, 15th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.24. The company had revenue of $93.67 million for the quarter, compared to analyst estimates of $89.75 million. Artivion had a negative net margin of 8.67% and a positive trailing twelve-month return on equity of 3.02%.

What ETFs hold Artivion's stock?

ETFs with the largest weight of Artivion (NYSE:AORT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH) . Unusual Whales Subversive Democratic Trading ETF (NANC) .

What guidance has Artivion issued on next quarter's earnings?

Artivion updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $382.0 million-$396.0 million, compared to the consensus revenue estimate of $384.3 million.

Who are Artivion's major shareholders?

Artivion's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (2.63%), Allspring Global Investments Holdings LLC (0.01%), Register Financial Advisors LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Amy Horton, Andrew M Green, David Ashley Lee, Dennis B Maier, James P Mackin , Jean F Holloway, John E Davis, Marshall S Stanton, Matthew A Getz and Rochelle L Maney. View institutional ownership trends .

How do I buy shares of Artivion?

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:AORT

Artivion (AORT) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free AORT Stock Alerts

$20.14

-0.07 (-0.35%)

(As of 02:18 PM ET)

Compare

Today's Range: $20.14
▼
$20.52
50-Day Range: $17.03
▼
$21.64
52-Week Range: $12.16
▼
$21.90

Volume: 44,008 shs
Average Volume: 221,083 shs
Market Capitalization: $829.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.50

Get Artivion alerts:

Artivion MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 15.1% Upside
$23.50 Price Target
Short Interest: Bearish
7.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$2.89 M Sold Last Quarter
Proj. Earnings Growth: 123.08%
From $0.26 to $0.58 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.28 out of 5 stars

Medical Sector

789th out of 918 stocks

Surgical & Medical Instruments Industry

82nd out of 97 stocks

2.5

Analyst's Opinion

Consensus Rating
Artivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Artivion has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
7.25% of the float of Artivion has been sold short.
Short Interest Ratio / Days to Cover
Artivion has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Artivion has recently increased by 3.27%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Artivion does not currently pay a dividend.
Dividend Growth
Artivion does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AORT.

2.2

News and Social Media Coverage

News Sentiment
Artivion has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
MarketBeat Follows
Only 5 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,891,627.00 in company stock.
Percentage Held by Insiders
Only 8.10% of the stock of Artivion is held by insiders.
Percentage Held by Institutions
86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Artivion are expected to grow by 123.08% in the coming year, from $0.26 to $0.58 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Artivion is -27.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Artivion is -27.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Artivion has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Artivion Stock (NYSE:AORT)

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

AORT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AORT Stock News Headlines

March 22, 2024 | insidertrades.com

Marshall S. Stanton Sells 2,183 Shares of Artivion, Inc. (NYSE:AORT) Stock

March 19, 2024 | insidertrades.com

Artivion, Inc. (NYSE:AORT) VP Sells $29,240.00 in Stock

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 19, 2024 | finance.yahoo.com

Artivion's (NYSE:AORT) investors will be pleased with their notable 43% return over the last year

April 11, 2024 | americanbankingnews.com

Artivion (NYSE:AORT) Hits New 52-Week High at $21.90

April 11, 2024 | americanbankingnews.com

Artivion (NYSE:AORT) Reaches New 12-Month High at $21.90

April 9, 2024 | americanbankingnews.com

Artivion (NYSE:AORT) Stock Rating Reaffirmed by Needham & Company LLC

April 1, 2024 | finance.yahoo.com

Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 20, 2024 | investing.com

Artivion's VP regulatory sells shares worth over $29k

March 17, 2024 | uk.investing.com

Artivion VP regulatory sells shares worth $79,880

March 16, 2024 | uk.investing.com

Artivion executive sells shares worth nearly $100k

March 6, 2024 | prnewswire.com

Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

February 21, 2024 | finance.yahoo.com

Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet

February 16, 2024 | finance.yahoo.com

Artivion, Inc. (NYSE:AORT) Q4 2023 Earnings Call Transcript

February 15, 2024 | msn.com

Artivion (AORT) Surpasses Q4 Earnings and Revenue Estimates

February 15, 2024 | finance.yahoo.com

Artivion Inc (AORT) Reports Solid Revenue Growth and Robust EBITDA Increase in Q4 and Full Year 2023

February 15, 2024 | finance.yahoo.com

Artivion Reports Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024 | prnewswire.com

Artivion Reports Fourth Quarter and Full Year 2023 Financial Results

February 14, 2024 | finance.yahoo.com

AORT Apr 2024 12.500 put

February 14, 2024 | benzinga.com

Artivion's Earnings: A Preview

February 1, 2024 | finance.yahoo.com

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results

January 29, 2024 | finance.yahoo.com

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting

January 21, 2024 | morningstar.com

Artivion Inc AORT

January 18, 2024 | finance.yahoo.com

Artivion Obtains $350 Million in Senior Secured Credit Facilities

January 15, 2024 | finance.yahoo.com

There Are Reasons To Feel Uneasy About Artivion's (NYSE:AORT) Returns On Capital

December 18, 2023 | finance.yahoo.com

Artivion, Inc. (NYSE:AORT) Soars 36% But It's A Story Of Risk Vs Reward

See More Headlines

Receive AORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NYSE:AORT
CUSIP: N/A
CIK: 784199
Web: www.cryolife.com
Phone: (770) 419-3355
Fax: 770-426-0031
Employees: 1,500
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $23.50
High Stock Price Target: $25.00
Low Stock Price Target: $22.00
Potential Upside/Downside: +16.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 77.73
P/E Growth: N/A
Net Income: $-30,690,000.00
Net Margins: -8.67%
Pretax Margin: -6.10%
Return on Equity: 3.02%
Return on Assets: 1.09%

Debt

Debt-to-Equity Ratio: 1.10
Current Ratio: 4.85
Quick Ratio: 3.43

Sales & Book Value

Annual Sales: $354 million
Price / Sales: 2.35
Cash Flow: $0.78 per share
Price / Cash Flow: 25.95
Book Value: $6.87 per share
Price / Book: 2.94

Miscellaneous

Outstanding Shares: 41,200,000
Free Float: 37,863,000
Market Cap: $832.65 million
Optionable: Optionable
Beta: 1.67

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. James Patrick Mackin (Age 57)
Chairman, President & CEO
Comp: $1.63M
Ms. Jean F. Holloway Esq. (Age 67)
Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
Comp: $636.72k
Mr. John E. Davis (Age 59)
Senior VP & Chief Commercial Officer
Comp: $609.91k
Dr. Marshall S. Stanton M.D. (Age 67)
Senior VP of Clinical Research & Chief Medical Officer
Comp: $615.55k
Ms. Amy D. Horton CPA (Age 54)
VP & Chief Accounting Officer
Mr. Matthew A. Getz (Age 55)
VP of Human Resources & Chief Human Resources Officer
Dr. Robert C. Thomson (Age 54)
Vice President of Research & Development
Mr. Florian Tyrs
Vice President of Global Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AORT Stock Analysis - Frequently Asked Questions

Should I buy or sell Artivion stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AORT shares.
View AORT analyst ratings or view top-rated stocks.
What is Artivion's stock price target for 2024?: 2 brokerages have issued 12 month price objectives for Artivion's shares. Their AORT share price targets range from $22.00 to $25.00. On average, they anticipate the company's share price to reach $23.50 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price.
View analysts price targets for AORT or view top-rated stocks among Wall Street analysts.
How have AORT shares performed in 2024?: Artivion's stock was trading at $17.88 at the beginning of 2024. Since then, AORT shares have increased by 14.1% and is now trading at $20.41.
View the best growth stocks for 2024 here.
When is Artivion's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AORT earnings forecast.
How were Artivion's earnings last quarter?: Artivion, Inc. (NYSE:AORT) issued its quarterly earnings results on Thursday, February, 15th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.24. The company had revenue of $93.67 million for the quarter, compared to analyst estimates of $89.75 million. Artivion had a negative net margin of 8.67% and a positive trailing twelve-month return on equity of 3.02%.

What ETFs hold Artivion's stock?: ETFs with the largest weight of Artivion (NYSE:AORT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH).Unusual Whales Subversive Democratic Trading ETF (NANC).
What guidance has Artivion issued on next quarter's earnings?: Artivion updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $382.0 million-$396.0 million, compared to the consensus revenue estimate of $384.3 million.
Who are Artivion's major shareholders?: Artivion's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (2.63%), Allspring Global Investments Holdings LLC (0.01%), Register Financial Advisors LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Amy Horton, Andrew M Green, David Ashley Lee, Dennis B Maier, James P Mackin, Jean F Holloway, John E Davis, Marshall S Stanton, Matthew A Getz and Rochelle L Maney.
View institutional ownership trends.
How do I buy shares of Artivion?: Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AORT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Artivion (AORT) Stock Price, News & Analysis

Artivion MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Artivion Stock (NYSE:AORT)

AORT Stock Price History

AORT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AORT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™